HEPATOCELLULAR CARCINOMA (HCC)

This study tests a new approach for people with liver cancer that is too large or numerous for standard transplant criteria but can still be surgically removed. Participants will receive a liver-directed treatment (TACE) plus an immunotherapy drug (QL1706) before surgery, then co…

This study looks at a procedure called irreversible electroporation (IRE) for people with liver cancer that hasn't spread. IRE uses electrical pulses to destroy tumor cells without cutting into the liver. The study will include 50 adults with good liver function and up to 3 small…

This phase 3 trial tests whether adding the experimental drug TPST-1120 to standard immunotherapy and anti-angiogenic therapy helps people with advanced liver cancer live longer. About 740 adults whose cancer cannot be surgically removed or has spread will receive either the trip…

This study tests a new treatment for people with advanced liver cancer that cannot be surgically removed. The approach combines a targeted drug (bevacizumab), an immunotherapy (adebrelimab), and two liver-directed procedures (TACE and HAIC) to shrink tumors and control the diseas…

This study tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab), a targeted therapy (lenvatinib), and a procedure called TACE in people with advanced liver cancer. The goal is to see if this mix can delay cancer growth. About 41 adults who have not had pr…

This study tests a combination of three treatments—FOLFOX-HAIC (chemotherapy directly into the liver), lenvatinib (a targeted drug), and tislelizumab (an immunotherapy)—in 38 adults with advanced liver cancer that has spread into the main portal vein. The goal is to shrink the tu…

This study tests a new treatment called SH006 injection combined with other drugs against a standard drug (regorafenib) for people with advanced liver cancer that has not responded to previous immunotherapy. The goal is to see if the new combination helps patients live longer wit…

This study tests two oral drugs, lenvatinib and regorafenib, in people with advanced liver cancer that worsened after initial immunotherapy. About 146 adults with varying liver function will take one of these pills daily. Researchers will measure how long the drugs control cancer…

This study tests the drug cabozantinib in 60 adults with advanced liver cancer that got worse after initial immunotherapy. The goal is to see if cabozantinib can stop or slow tumor growth for at least 6 months. Researchers will also look for blood or tissue markers that predict w…

This study looks at whether giving a bone-strengthening drug (denosumab) early, along with standard immunotherapy, can prevent bone problems like fractures or spinal cord compression in people with liver cancer that has spread to the bones. About 50 adults aged 18 to 75 will be r…

This early-phase study tests a new drug called CRPA1A2 in people with advanced solid tumors (lung, esophagus, head and neck, or liver cancer) that have not responded to standard treatments. The drug is designed to help the body's immune cells attack cancer cells that have a speci…

This study tests a combination of two drugs (Benmelstobart and Anlotinib) plus targeted radiation (SBRT) in 29 adults with liver cancer that has spread to a few spots and stopped responding to initial therapy. The goal is to see if this triple approach can slow or stop cancer gro…

This study tests whether adding a traditional Chinese medicine formula (Fufang Biejiaruangan) to standard antiviral therapy can lower the chance of developing liver cancer in people with hepatitis B-related cirrhosis. About 1,034 high-risk adults (ages 18-65) will be randomly ass…

This study tests whether adding Babao Dan Capsule, a traditional Chinese medicine, to standard antiviral therapy can lower the chance of developing liver cancer in people with hepatitis B-related cirrhosis who are at high risk. About 1,034 participants will be randomly assigned t…

This study tests a new drug called BB102 for people with advanced liver cancer that has not responded to other treatments. The drug targets a specific protein (FGF19) found in some liver cancers. The goal is to see if BB102 can shrink tumors or slow cancer growth, with 60 partici…

This early-phase trial tests a new treatment called Meta10-GPC3 for people with advanced liver cancer that cannot be removed by surgery. The therapy uses the patient's own immune cells, modified to better recognize and attack cancer cells. The main goal is to check safety, and re…

This study tests whether adding a liver-directed chemotherapy infusion (HAIC) to a two-drug combination (lenvatinib and a PD-1 inhibitor) works better than the two drugs alone for people with advanced liver cancer that has invaded major blood vessels or bile ducts. About 150 adul…

This study looks at people with liver cancer that has spread outside the liver. It tests whether surgically removing the main liver tumor, along with standard drug therapy, helps them live longer compared to drug therapy alone. About 280 adults aged 18-75 with a resectable liver …

This study tests a new approach for people with advanced liver cancer whose first-line treatment stopped working. It combines a special type of radiation (PULSAR) with a fecal microbiota transplant (FMT) to try to make the original treatment effective again. About 64 participants…

This study tests whether adding fostrox to lenvatinib works better than lenvatinib alone for people with advanced liver cancer that got worse after first immunotherapy. About 80 adults will be randomly assigned to one of two groups. The goal is to see if the combination shrinks t…

This study tests a personalized approach for people with advanced liver cancer that cannot be removed by surgery. Researchers will analyze the tumor's metabolism (how it uses fat for energy) to assign each patient to a specific treatment combination. The goal is to see if this ta…

This study compares two treatments for small liver cancer: surgery and a precise type of radiation called SBRT. About 312 adults with a single tumor 5 cm or smaller will be randomly assigned to one of the two treatments. The main goal is to see which approach helps people live lo…

This study looks at 120 adults with advanced hepatitis B-related liver cancer who are starting immunotherapy. It compares two antiviral strategies: taking TAF alone versus taking both ETV and TAF. The goal is to see which approach helps people live longer and better controls the …

This study looks at people with liver cancer that has spread to a few spots outside the liver. All participants first get a combination of two drugs (sintilimab and lenvatinib). Those whose cancer is controlled are then randomly assigned to either continue the drugs alone or also…

This study is testing a new blood test that looks for specific genetic markers (GNB4 and Riplet gene methylation) to detect if liver cancer has come back after treatment. About 162 adults who have had or will have surgery, transplant, ablation, or chemoembolization for liver canc…

This study tests whether ondansetron, a drug used for nausea, can lower the risk and severity of side effects from immunotherapy in people with liver cancer. About 134 patients will receive ondansetron or a placebo alongside their standard cancer treatment. The goal is to see if …

This study tests a drug called nanocrystalline megestrol acetate to see if it can prevent weight loss and improve appetite in people with advanced liver cancer who are already receiving standard treatments. About 88 participants will be randomly assigned to receive either the dru…

This study will look at 2,000 liver cancer patients to understand why some respond better than others to a mix of interventional and systemic therapies. Researchers will track tumor progression, side effects, and quality of life, then use machine learning to predict risks. The go…

This study looks at whether blood-based biomarkers can predict and monitor how well liver cancer responds to a standard treatment called TACE. Researchers will collect blood samples from 60 adults with liver cancer before and after TACE, then compare the results with CT or MRI sc…

This study aims to create an AI tool that analyzes standard liver cancer tissue images to predict which patients will benefit from additional treatments after surgery. The goal is to avoid unnecessary side effects and improve outcomes by personalizing care. The study will involve…

This study will enroll 66 adults with liver cancer (hepatocellular carcinoma) who are scheduled for either transarterial chemoembolization (TACE) or microwave ablation (MWA). Researchers will use CT scans to measure tumor volume before and after treatment to see if this method ca…

This study tests whether artificial intelligence (AI) can help doctors decide between two common treatments for early-stage liver cancer: surgery or microwave ablation. The AI will analyze ultrasound and MRI scans to predict which patients are likely to have their cancer return w…